2-Step Gene Sequencing Shows Who May Respond to Cancer Immunotherapy
The promise of so-called immune checkpoint inhibitors and other targeted immunotherapies for cancer is that they can destroy some hard-to-treat tumors much more effectively than old-school chemotherapy.But there’s a big problem with immunotherapies, too. These drugs, which train the immune system to find and kill cancer cells, work only in a small subset of patients, and it’s really hard to determine in advance who will benefit.Right now, doctors often look at several biomarkers, like age, tumor type, and the number of mutations found in cancer cells, to predict who might benefit from immunotherapy. Looking at mutations on a few hundred genes is the main way to determine if patients might benefit from immune checkpoint inhibitors, which per the American Cancer Society target “checkpoint” proteins on immune cells that can switch…